Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis

Figures & data

Figure 1 Updated network of evidence.

Abbreviations: BID, twice daily; FDC, fixed-dose combinations; FOR/BUD, FDC formoterol and budesonide; ICS, inhaled corticosteroids; OD, once daily; SAL/FP, salmeterol and fluticasone proprionate.

Table 1 Results of network meta-analysis for FEV₁ and TDI at 12 weeks: indacaterol 75 μg versus alternatives without and with covariates

	Without adjustment for covariates		With adjustment for covariates
	Difference in change from baseline (95% CrI)	Probability of IND 75 being better	Difference in change from baseline (95% CrI)	Probability of IND 75 being better
FEV1 at 12 weeks
Placebo	0.16 (0.12–0.20)	> 99%	0.15 (0.10–0.20)	>99%
SAL/FP 50/500	0.01 (−0.04–0.05)	62%	0.00 (−0.07–0.07)	52%
SAL/FP 50/250	0.00 (−0.07–0.07)	52%	0.00 (−0.10–0.10)	49%
FOR/BUD 9/320	0.07 (0.03–0.11)	>99%	0.07 (−0.03–0.16)	92%
FOR/BUD 9/160	0.09 (0.04–0.13)	>99%	0.09 (−0.01–0.18)	96%
TDI at 12 weeks
Placebo	0.90 (−0.01–1.81)	97%	0.81 (−0.37–2.00)	91%
SAL/FP 50/500	−0.49 (−1.87–0.89)	25%	−1.80 (−6.01–2.37)	20%

Abbreviations: 95% CrI, 95% credible interval; SAL/FP, fixed-dose combination salmeterol and fluticasone; FOR/BUD, fixed-dose combination of formoterol and budesonide; IND, indacaterol; TDI, transitional dyspnea; FEV₁, forced expiratory volume in 1 second.